Fangzhou Jianke (06086) surged over 7% during trading hours. As of press time, the stock was up 6.65% to HK$4.65, with a turnover of HK$28.54 million.

On the news front, on September 10, at Fangzhou Jianke's 10th H2H Healthcare Service Ecosystem Conference, the leading domestic AI+chronic disease management company Fangzhou Jianke formally signed a strategic cooperation agreement with Innovent Bio.

According to the announcement, Fangzhou Jianke will leverage its AI technology achievements, H2H smart healthcare ecosystem, and digital industry experience to reshape the full-cycle management process for chronic disease patients, creating a personalized and integrated health management experience.

Building on this strategic partnership, both parties will capitalize on their respective strengths to drive deep integration between innovative treatment solutions and AI-powered digital health management, jointly establishing a new service paradigm in the "AI+weight management" field.

Specifically, in pharmaceutical services, leveraging the real-time response capabilities of AI medication assistants, obesity patients can receive immediate access to 24/7 online consultations, medication sourcing, and medication Q&A support without waiting, completely breaking the traditional time and space limitations of pharmaceutical services.

In weight management, AI health stewards serve as patients' round-the-clock health management partners, providing personalized medication guidance, service reminders and management, report interpretation, and educational content. This not only provides psychological comfort but also reduces decision-making costs, effectively enhancing patients' health literacy and self-management capabilities.